Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.
BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, announced a strategic collaboration to co-develop therapies.